Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors NCT02496208 Bladder Small C...
Bladder Squamou...
Bladder Urothel...
Clear Cell Rena...
Invasive Bladde...
Invasive Bladde...
Invasive Sarcom...
Kidney Medullar...
Malignant Genit...
Malignant Solid...
Penile Carcinom...
Penile Squamous...
Renal Cell Carc...
Renal Pelvis Ur...
Sarcomatoid Ren...
Stage III Bladd...
Stage III Penil...
Stage III Renal...
Stage III Renal...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Penile...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Ureter Urotheli...
Urethral Urothe...
Biopsy
Biospecimen Col...
Cabozantinib S-...
Computed Tomogr...
Echocardiograph...
Ipilimumab
Magnetic Resona...
Nivolumab
18 Years - National Cancer Institute (NCI) View Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology NCT05756569 Bladder Squamou...
Locally Advance...
Malignant Renal...
Malignant Urete...
Malignant Ureth...
Metastatic Blad...
Stage III Bladd...
Stage IV Bladde...
Unresectable Bl...
Urachal Adenoca...
Bladder Adenoca...
Biospecimen Col...
Computed Tomogr...
Enfortumab Vedo...
Magnetic Resona...
Pembrolizumab
Questionnaire A...
18 Years - Emory University View Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study NCT05092958 Advanced Bladde...
Advanced Renal ...
Advanced Ureter...
Advanced Urethr...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Stage III Bladd...
Stage III Renal...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Avelumab
Biospecimen Col...
Bone Scan
Cabozantinib S-...
Computed Tomogr...
Magnetic Resona...
Quality-of-Life...
Questionnaire A...
18 Years - National Cancer Institute (NCI) View Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors NCT02496208 Bladder Small C...
Bladder Squamou...
Bladder Urothel...
Clear Cell Rena...
Invasive Bladde...
Invasive Bladde...
Invasive Sarcom...
Kidney Medullar...
Malignant Genit...
Malignant Solid...
Penile Carcinom...
Penile Squamous...
Renal Cell Carc...
Renal Pelvis Ur...
Sarcomatoid Ren...
Stage III Bladd...
Stage III Penil...
Stage III Renal...
Stage III Renal...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Penile...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Ureter Urotheli...
Urethral Urothe...
Biopsy
Biospecimen Col...
Cabozantinib S-...
Computed Tomogr...
Echocardiograph...
Ipilimumab
Magnetic Resona...
Nivolumab
18 Years - National Cancer Institute (NCI) View Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma NCT03513952 Advanced Bladde...
Advanced Ureter...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Glycosylated Re...
Laboratory Biom...
Magnetic Resona...
Positron Emissi...
18 Years - National Cancer Institute (NCI) View Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy NCT04963153 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Biospecimen Col...
Computed Tomogr...
Enfortumab Vedo...
Erdafitinib
18 Years - National Cancer Institute (NCI) View An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers NCT06414317 Locally Advance...
Metastatic Blad...
Stage III Bladd...
Stage IV Bladde...
Unresectable Bl...
Assessment of D...
Consultation Vi...
Nutritional Ass...
Questionnaire A...
Supportive Care
Supportive Care
18 Years - Roswell Park Cancer Institute View Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression NCT04953104 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center View Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression NCT04953104 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center View Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma NCT04940299 Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Malignant Solid...
Metastatic Blad...
Metastatic Blad...
Metastatic Lung...
Metastatic Mela...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Uret...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Lung ...
Stage IVB Lung ...
Unresectable Me...
Ipilimumab
Nivolumab
Tocilizumab
18 Years - M.D. Anderson Cancer Center View Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies NCT04902040 Advanced Bladde...
Advanced Lung N...
Advanced Malign...
Advanced Melano...
Advanced Merkel...
Advanced Renal ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IVA Bladd...
Stage IVA Lung ...
Stage IVB Bladd...
Stage IVB Lung ...
Atezolizumab
Avelumab
Durvalumab
Nivolumab
Pembrolizumab
Plinabulin
Radiation Thera...
18 Years - M.D. Anderson Cancer Center View Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression NCT04953104 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center View Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies NCT04902040 Advanced Bladde...
Advanced Lung N...
Advanced Malign...
Advanced Melano...
Advanced Merkel...
Advanced Renal ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IVA Bladd...
Stage IVA Lung ...
Stage IVB Bladd...
Stage IVB Lung ...
Atezolizumab
Avelumab
Durvalumab
Nivolumab
Pembrolizumab
Plinabulin
Radiation Thera...
18 Years - M.D. Anderson Cancer Center View Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes NCT03375307 Advanced Bladde...
Advanced Genito...
Metastatic Blad...
Metastatic Geni...
Stage III Bladd...
Stage IV Bladde...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Bone Scan
Computed Tomogr...
Magnetic Resona...
Olaparib
Positron Emissi...
18 Years - National Cancer Institute (NCI) View Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913 Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Hepatobiliary N...
Malignant Diges...
Malignant Femal...
Malignant Genit...
Malignant Neopl...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Stage 0 Colorec...
Stage 0a Bladde...
Stage 0is Bladd...
Stage I Bladder...
Stage I Cervica...
Stage I Colorec...
Stage I Ovarian...
Stage I Prostat...
Stage I Renal C...
Stage I Uterine...
Stage IA Cervic...
Stage IA Ovaria...
Stage IA Uterin...
Stage IA1 Cervi...
Stage IA2 Cervi...
Stage IB Cervic...
Stage IB Ovaria...
Stage IB Uterin...
Stage IB1 Cervi...
Stage IB2 Cervi...
Stage IC Ovaria...
Stage II Bladde...
Stage II Cervic...
Stage II Colore...
Stage II Ovaria...
Stage II Prosta...
Stage II Renal ...
Stage II Uterin...
Stage IIA Cervi...
Stage IIA Color...
Stage IIA Ovari...
Stage IIA Prost...
Stage IIA1 Cerv...
Stage IIA2 Cerv...
Stage IIB Cervi...
Stage IIB Color...
Stage IIB Ovari...
Stage IIB Prost...
Stage IIC Color...
Stage IIC Prost...
Stage III Bladd...
Stage III Cervi...
Stage III Color...
Stage III Ovari...
Stage III Prost...
Stage III Renal...
Stage III Uteri...
Stage IIIA Blad...
Stage IIIA Cerv...
Stage IIIA Colo...
Stage IIIA Ovar...
Stage IIIA Pros...
Stage IIIA Uter...
Stage IIIA1 Ova...
Stage IIIA2 Ova...
Stage IIIB Blad...
Stage IIIB Cerv...
Stage IIIB Colo...
Stage IIIB Ovar...
Stage IIIB Pros...
Stage IIIB Uter...
Stage IIIC Colo...
Stage IIIC Ovar...
Stage IIIC Pros...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Bladde...
Stage IV Cervic...
Stage IV Colore...
Stage IV Ovaria...
Stage IV Prosta...
Stage IV Renal ...
Stage IV Uterin...
Stage IVA Bladd...
Stage IVA Cervi...
Stage IVA Color...
Stage IVA Ovari...
Stage IVA Prost...
Stage IVA Uteri...
Stage IVB Bladd...
Stage IVB Cervi...
Stage IVB Color...
Stage IVB Ovari...
Stage IVB Prost...
Stage IVB Uteri...
Stage IVC Color...
Patient Monitor...
Questionnaire A...
18 Years - City of Hope Medical Center View Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer NCT04936230 Metastatic Urot...
Platinum-Resist...
Stage IV Bladde...
Biospecimen Col...
Bone Scan
Computed Tomogr...
Magnetic Resona...
Pembrolizumab
Positron Emissi...
Questionnaire A...
Stereotactic Bo...
18 Years - National Cancer Institute (NCI) View Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate NCT03582475 Bladder Small C...
Castration-Resi...
Metastatic Blad...
Metastatic Uret...
Prostate Carcin...
Prostate Neuroe...
Prostate Small ...
Stage III Bladd...
Stage III Prost...
Stage III Ureth...
Stage IV Bladde...
Stage IV Prosta...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Ureter Small Ce...
Urothelial Carc...
Carboplatin
Cisplatin
Docetaxel
Etoposide
Pembrolizumab
18 Years - Jonsson Comprehensive Cancer Center View Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma NCT04848519 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Pembrolizumab
Propranolol Hyd...
Nivolumab
Avelumab
18 Years - Emory University View Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression NCT04953104 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center View Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer NCT03237780 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Eribulin Mesyla...
18 Years - National Cancer Institute (NCI) View Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology NCT05756569 Bladder Squamou...
Locally Advance...
Malignant Renal...
Malignant Urete...
Malignant Ureth...
Metastatic Blad...
Stage III Bladd...
Stage IV Bladde...
Unresectable Bl...
Urachal Adenoca...
Bladder Adenoca...
Biospecimen Col...
Computed Tomogr...
Enfortumab Vedo...
Magnetic Resona...
Pembrolizumab
Questionnaire A...
18 Years - Emory University View Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer NCT03237780 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Eribulin Mesyla...
18 Years - National Cancer Institute (NCI) View Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer NCT04579224 Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Refractory Blad...
Refractory Rena...
Refractory Uret...
Refractory Uret...
Refractory Urot...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Biospecimen Col...
Bone Scan
Computed Tomogr...
Docetaxel
Eribulin Mesyla...
Gemcitabine Hyd...
Magnetic Resona...
Paclitaxel
Sacituzumab Gov...
18 Years - National Cancer Institute (NCI) View Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 Bladder Adenoca...
Bladder Clear C...
Bladder Mixed A...
Bladder Neuroen...
Bladder Small C...
Bladder Squamou...
Chromophobe Ren...
Collecting Duct...
Invasive Bladde...
Invasive Bladde...
Invasive Bladde...
Invasive Bladde...
Invasive Bladde...
Invasive Bladde...
Kidney Medullar...
Large Cell Neur...
Malignant Testi...
Malignant Testi...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Blad...
Metastatic Chro...
Metastatic Kidn...
Metastatic Mali...
Metastatic Papi...
Metastatic Peni...
Metastatic Pros...
Metastatic Sarc...
Metastatic Uret...
Papillary Renal...
Sarcomatoid Ren...
Stage IV Bladde...
Stage IV Penile...
Stage IV Renal ...
Stage IV Urethr...
Stage IVB Prost...
Urachal Adenoca...
Urethral Clear ...
Bone Scan
Cabozantinib S-...
Computed Tomogr...
Ipilimumab
Magnetic Resona...
Nivolumab
Positron Emissi...
18 Years - National Cancer Institute (NCI) View